BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18075467)

  • 1. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
    Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
    Pharmacogenet Genomics; 2008 Jan; 18(1):25-35. PubMed ID: 18216719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
    Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
    Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.
    Ezzeldin H; Okamoto Y; Johnson MR; Diasio RB
    Anal Biochem; 2002 Jul; 306(1):63-73. PubMed ID: 12069415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydropyrimidine dehydrogenase deficiency in an Indian population.
    Saif MW; Mattison L; Carollo T; Ezzeldin H; Diasio RB
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):396-401. PubMed ID: 16421754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; DoĊ‚egowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.
    Johnson MR; Wang K; Diasio RB
    Clin Cancer Res; 2002 Mar; 8(3):768-74. PubMed ID: 11895907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase activity during long-term adjuvant treatment with oral uracil and tegafur for colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Ishikawa K; Tanaka Y; Yasuda S; Kamijo A; Makuuchi H; Murayama C
    Chemotherapy; 2007; 53(6):442-5. PubMed ID: 17952005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function.
    Van Kuilenburg AB; Meinsma R; Beke E; Bobba B; Boffi P; Enns GM; Witt DR; Dobritzsch D
    Biol Chem; 2005 Apr; 386(4):319-24. PubMed ID: 15899693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
    Ogura K; Ohnuma T; Minamide Y; Mizuno A; Nishiyama T; Nagashima S; Kanamaru M; Hiratsuka A; Watabe T; Uematsu T
    Clin Cancer Res; 2005 Jul; 11(14):5104-11. PubMed ID: 16033824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
    Fidlerova J; Kleiblova P; Bilek M; Kormunda S; Formankova Z; Novotny J; Kleibl Z
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):661-9. PubMed ID: 19649633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
    Weidensee S; Goettig P; Bertone M; Haas D; Magdolen V; Kiechle M; Meindl A; van Kuilenburg AB; Gross E
    Clin Biochem; 2011 Jun; 44(8-9):722-4. PubMed ID: 21420945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.